Preparation and characterization of size-controlled glioma spheroids using agarose hydrogel microwells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
10
2018
accepted:
07
01
2019
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
24
10
2019
Statut:
epublish
Résumé
Treatment of glioblastoma, the most common and aggressive type of primary brain tumors, is a major medical challenge and the development of new alternatives requires simple yet realistic models for these tumors. In vitro spheroid models offer attractive platforms to mimic the tumor behavior in vivo and have thus, been increasingly applied for assessment of drug efficacy in various tumors. The aim of this study was to produce and characterize size-controlled U251 glioma spheroids towards application in glioma drug evaluation studies. To this end, we fabricated agarose hydrogel microwells with cylindrical shape and diameters of 70-700 μm and applied these wells without any surface modification for glioma spheroid formation. The resultant spheroids were homogeneous in size and shape, exhibited high cell viability (> 90%), and had a similar growth rate to that of natural brain tumors. The final size of spheroids depended on cell seeding density and microwell size. The spheroids' volume increased linearly with the cell seeding density and the rate of this change increased with the well size. Lastly, we tested the therapeutic effect of an anti-cancer drug, Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) on the resultant glioma spheroids and demonstrated the applicability of this spheroid model for drug efficacy studies.
Identifiants
pubmed: 30677075
doi: 10.1371/journal.pone.0211078
pii: PONE-D-18-29481
pmc: PMC6345430
doi:
Substances chimiques
Hydrogels
0
Sepharose
9012-36-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211078Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biomaterials. 2006 Oct;27(30):5259-67
pubmed: 16814859
Analyst. 2011 Feb 7;136(3):473-8
pubmed: 20967331
J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24
pubmed: 22797912
J Pharm Sci. 2011 Jan;100(1):59-74
pubmed: 20533556
Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83
pubmed: 19555299
Biotechniques. 2007 Oct;43(4):494, 496-500
pubmed: 18019341
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80
pubmed: 12768623
Curr Oncol. 2015 Aug;22(4):e273-81
pubmed: 26300678
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
ACS Biomater Sci Eng. 2018 Feb 12;4(2):410-420
pubmed: 29527571
PLoS One. 2015 Jun 19;10(6):e0130348
pubmed: 26090664
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14901-6
pubmed: 17003122
Mol Cancer Ther. 2009 Mar;8(3):648-54
pubmed: 19276162
PLoS One. 2012;7(11):e50491
pubmed: 23226295
Adv Mater. 2013 Dec 17;25(47):6834-8
pubmed: 24133042
Biomaterials. 2016 Mar;81:72-83
pubmed: 26724455
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:309-312
pubmed: 29059872
Methods Mol Biol. 2009;559:19-32
pubmed: 19609746
Angew Chem Int Ed Engl. 2005 Oct 21;44(41):6697-700
pubmed: 16187388
Am J Hematol. 2009 Mar;84(3):170-6
pubmed: 19140186
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:5733-5736
pubmed: 30441638
Lab Chip. 2007 Jun;7(6):786-94
pubmed: 17538722
Science. 1988 Apr 8;240(4849):177-84
pubmed: 2451290
Sci Adv. 2018 Apr 27;4(4):eaas8998
pubmed: 29719868
Biochem Eng J. 2018 Mar 15;131:39-46
pubmed: 29736144
J Biomed Mater Res A. 2010 May;93(2):547-57
pubmed: 19585570
Cancer Res. 2011 Sep 1;71(17):5871-80
pubmed: 21750178
Lab Chip. 2010 Sep 21;10(18):2411-8
pubmed: 20664846
Acta Biomater. 2018 Jul 15;75:11-34
pubmed: 29803007
Neuro Oncol. 2015 Oct;17(10):1402-11
pubmed: 25758748
PLoS One. 2011;6(6):e20614
pubmed: 21698233
IEEE J Transl Eng Health Med. 2015 Mar 05;3:4300108
pubmed: 27170911